Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Fosinopril
Price:
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang

98048-97-6

98048-97-6 structure

Name: Fosinopril
Chemical Name: fosinopril
CAS Number: 98048-97-6
Molecular Formula: C₃₀H₄₆NO₇P
Molecular Weight: 563.66300
Catalog: API Circulatory system medication Antihypertensive drug
Create Date: 2018-08-27 15:48:51
Modify Date: 2024-01-02 11:30:23
Fosinopril (SQ28555) is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value of 0.18 μM[1]. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2].

Name	fosinopril
Synonyms	fosenopril Staril Fosinopril MFCD00870759 Secorvas

Description	Fosinopril (SQ28555) is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value of 0.18 μM[1]. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Angiotensin-converting Enzyme (ACE)
Target	IC50: 0.18 μM; Ki: 1.675 μM
In Vitro	Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2[1]. Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2[1]. Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2].
In Vivo	Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration[3]. Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model[3]. Animal Model: HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g) [3] Dosage: 4.67 mg/kg Administration: p.o.; 4 weeks Result: Against cardiac dysfunction and structural alteration and suppressed apoptosis.
References	[1]. Ondetti, M.A., Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation, 1988. 77(6 Pt 2): p. I74-8. [2]. Piepho, R.W., Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm, 2000. 57 Suppl 1: p. S3-7. [3]. Sharma, S., et al., The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther, 1999. 6(4): p. 181-9.

Density	1.173 g/cm3
Boiling Point	705.7ºC at 760 mmHg
Melting Point	149-153ºC
Molecular Formula	C₃₀H₄₆NO₇P
Molecular Weight	563.66300
Flash Point	380.6ºC
Exact Mass	563.30100
PSA	120.02000
LogP	6.05920
Index of Refraction	1.531
Water Solubility	Insoluble

HS Code	2942000000

HS Code	2942000000

98048-97-6	134845-41-3
88889-14-9	474382-67-7
1217513-43-3	474519-28-3
137590-32-0	474382-60-0
1217819-83-4	46348-61-2
1158522-08-7	940364-43-2
134104-43-1	2680788-51-4
131615-57-1	6906-52-1
2436575-98-1	2229555-10-4
930439-75-1	1018584-77-4